Migraine - Reyvow Prior Authorization Policy
Cigna prior authorization policy for Reyvow (lasmiditan tablets) for acute treatment of migraine in adults; defines medical necessity criteria, coverage duration, contraindication examples, and that other uses are investigational.
Annual review completed with no criteria changes noted as of 08/07/2024.
Coverage Summary
Scope: Cigna prior authorization policy for Reyvow (lasmiditan tablets) for acute treatment of migraine in adults; defines medical necessity criteria, coverage duration, contraindication examples, and that other uses are investigational.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.